BWA
RYTM icon

Basecamp Wealth Advisors’s Rhythm Pharmaceuticals RYTM Stock Holding History

Basecamp Wealth Advisors’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.4K Sell
94
-20
-18% -$1.81K ﹤0.01% 997
2026
Q1 		$9.91K Sell
114
-11
-9% -$1.07K ﹤0.01% 1024
2025
Q4 		$13.4K Buy
+125
New +$13.3K ﹤0.01% 893

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Basecamp Wealth Advisors's RYTM Position: Q2 2026 in Review

Basecamp Wealth Advisors reduced its Rhythm Pharmaceuticals (RYTM) stake by 18% in Q2 2026, selling an estimated $1.81K and leaving 94 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #997.

Basecamp Wealth Advisors first reported a position in RYTM in Q4 2025 and has held it in 3 quarters since. The position peaked at $13.4K in Q4 2025. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Basecamp Wealth Advisors held 94 shares of Rhythm Pharmaceuticals worth $10.4K as of Q2 2026.
  • Basecamp Wealth Advisors sold 20 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $1.81K.
  • Rhythm Pharmaceuticals made up ﹤0.01% of Basecamp Wealth Advisors's portfolio in Q2 2026, its #997 holding.
  • Basecamp Wealth Advisors first reported a position in Rhythm Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Basecamp Wealth Advisors's Rhythm Pharmaceuticals position peaked at $13.4K in Q4 2025.
  • 303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Basecamp Wealth Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.